These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 7515450)
1. Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. Partin AW; Walsh PC J Urol; 1994 Jul; 152(1):172-3. PubMed ID: 7515450 [No Abstract] [Full Text] [Related]
2. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. Partin AW; Yoo J; Carter HB; Pearson JD; Chan DW; Epstein JI; Walsh PC J Urol; 1993 Jul; 150(1):110-4. PubMed ID: 7685418 [TBL] [Abstract][Full Text] [Related]
3. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update. Walsh PC J Urol; 1997 Oct; 158(4):1618-9. PubMed ID: 9302186 [No Abstract] [Full Text] [Related]
4. Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. Roach M J Urol; 1993 Dec; 150(6):1923-4. PubMed ID: 7693984 [No Abstract] [Full Text] [Related]
5. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database. Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968 [TBL] [Abstract][Full Text] [Related]
6. [Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer--a multi-institutional update]. Graefen M Aktuelle Urol; 2004 Sep; 35(5):377-8. PubMed ID: 15384003 [No Abstract] [Full Text] [Related]
7. Comparison of prostate specific antigen with prostate specific antigen density for 3 clinical applications. Shinohara K; Wolf JS; Narayan P; Carroll PR J Urol; 1994 Jul; 152(1):120-3. PubMed ID: 7515447 [TBL] [Abstract][Full Text] [Related]
8. Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density. Blackwell KL; Bostwick DG; Myers RP; Zincke H; Oesterling JE J Urol; 1994 Jun; 151(6):1565-70. PubMed ID: 7514689 [TBL] [Abstract][Full Text] [Related]
9. Prediction of pathological stage based on clinical stage, serum prostate-specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era. Tosoian JJ; Chappidi M; Feng Z; Humphreys EB; Han M; Pavlovich CP; Epstein JI; Partin AW; Trock BJ BJU Int; 2017 May; 119(5):676-683. PubMed ID: 27367645 [TBL] [Abstract][Full Text] [Related]
10. [PSA 2010--the beginning of a new era in early detection of prostate cancer]. Börgermann C; Sieverding M; Fornara P; Graefen M; Hammerer P; Semjonow A; Schröder F; Rübben H Urologe A; 2006 Sep; 45 Suppl 4():127-33. PubMed ID: 16941115 [No Abstract] [Full Text] [Related]
11. Predicting prostate specific antigen failure after radical retropubic prostatectomy for T1c prostate cancer. Ou YC; Chen JT; Yang CR; Cheng CL; Ho HC; Ko JL; Hsieh YS Jpn J Clin Oncol; 2002 Dec; 32(12):536-42. PubMed ID: 12578903 [TBL] [Abstract][Full Text] [Related]
12. Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? Lynch MJ J Urol; 2005 Sep; 174(3):1155; author reply 1155-6. PubMed ID: 16094096 [No Abstract] [Full Text] [Related]
13. What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group. Teeter AE; Bañez LL; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ; J Urol; 2008 Nov; 180(5):1980-4; discussion 1985. PubMed ID: 18801519 [TBL] [Abstract][Full Text] [Related]
14. Prostate specific antigen level and Gleason score in predicting the stage of newly diagnosed prostate cancer. Spencer JA; Chng WJ; Hudson E; Boon AP; Whelan P Br J Radiol; 1998 Nov; 71(851):1130-5. PubMed ID: 10434906 [TBL] [Abstract][Full Text] [Related]
15. The significance of De Ritis (aspartate transaminase/alanine transaminase) ratio in predicting pathological outcomes and prognosis in localized prostate cancer patients. Wang H; Fang K; Zhang J; Jiang Y; Wang G; Zhang H; Chen T; Shi X; Li Y; Duan F; Liu J Int Urol Nephrol; 2017 Aug; 49(8):1391-1398. PubMed ID: 28550473 [TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen velocity is not better than total prostate-specific antigen in predicting prostate biopsy diagnosis. Gorday W; Sadrzadeh H; de Koning L; Naugler CT Clin Biochem; 2015 Dec; 48(18):1230-4. PubMed ID: 26164541 [TBL] [Abstract][Full Text] [Related]
17. [Prostate cancer screening with a new marker based on circulating blood macrophages?]. Herwig R; Djavan B; Kramer G; El-Taieb MA; Kühhas F; Leers M; Marberger M Urologe A; 2007 Sep; 46(9):1066-70. PubMed ID: 17622505 [No Abstract] [Full Text] [Related]
18. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. Partin AW; Carter HB; Chan DW; Epstein JI; Oesterling JE; Rock RC; Weber JP; Walsh PC J Urol; 1990 Apr; 143(4):747-52. PubMed ID: 1690309 [TBL] [Abstract][Full Text] [Related]
19. Minimal impact of clinical stage on prostate cancer prognosis among contemporary patients with clinically localized disease. Reese AC; Cooperberg MR; Carroll PR J Urol; 2010 Jul; 184(1):114-9. PubMed ID: 20478578 [TBL] [Abstract][Full Text] [Related]
20. Prostate cancer: detection, staging, and treatment of localized disease. Potter SR; Partin AW Semin Roentgenol; 1999 Oct; 34(4):269-83. PubMed ID: 10553603 [No Abstract] [Full Text] [Related] [Next] [New Search]